E Fund Management Co. Ltd. Takes $597,000 Position in Kymera Therapeutics, Inc. $KYMR

E Fund Management Co. Ltd. purchased a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 5,209 shares of the company’s stock, valued at approximately $597,000.

A number of other large investors also recently bought and sold shares of the business. GAMMA Investing LLC boosted its stake in Kymera Therapeutics by 27.5% during the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock worth $52,000 after acquiring an additional 98 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after purchasing an additional 424 shares during the last quarter. Larson Financial Group LLC lifted its holdings in shares of Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Kymera Therapeutics in the 4th quarter worth approximately $63,000. Finally, Osaic Holdings Inc. boosted its position in shares of Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares in the last quarter.

Insider Buying and Selling

In related news, Director Bruce Booth sold 31,283 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $109.48, for a total transaction of $3,424,862.84. Following the completion of the sale, the director owned 461,794 shares in the company, valued at approximately $50,557,207.12. This represents a 6.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Noah Goodman sold 3,389 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $114.29, for a total value of $387,328.81. Following the completion of the transaction, the insider directly owned 47,179 shares in the company, valued at approximately $5,392,087.91. This represents a 6.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,604,813 shares of company stock valued at $387,557,004 over the last ninety days. 15.98% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on KYMR. Morgan Stanley reaffirmed an “overweight” rating and set a $135.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, August 6th. Citigroup reissued a “buy” rating on shares of Kymera Therapeutics in a report on Thursday, August 6th. BTIG Research reissued a “buy” rating and issued a $134.00 target price on shares of Kymera Therapeutics in a research note on Thursday, June 25th. Royal Bank Of Canada downgraded Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and raised their price target for the company from $106.00 to $115.00 in a report on Monday, July 13th. Finally, Barclays upped their price target on shares of Kymera Therapeutics from $133.00 to $139.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Twenty investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $125.65.

Kymera Therapeutics Trading Down 4.6%

Shares of KYMR stock opened at $121.50 on Friday. Kymera Therapeutics, Inc. has a 12-month low of $39.84 and a 12-month high of $130.05. The stock has a market capitalization of $10.10 billion, a P/E ratio of -37.50 and a beta of 1.95. The firm’s 50 day moving average is $108.75 and its 200 day moving average is $91.84.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.09. The business had revenue of $65.00 million during the quarter, compared to analyst estimates of $32.78 million. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The company’s quarterly revenue was up 465.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.95) EPS. As a group, equities analysts predict that Kymera Therapeutics, Inc. will post -3.75 earnings per share for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.